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Complement activation in myasthenia gravis (MG) may damage muscle endplate and complement regulatory proteins such as
decay-accelerating factor (DAF) or CD55 may be protective. We hypothesize that the increased prevalence of severe
extraocular muscle (EOM) dysfunction among African MG subjects reported earlier may result from altered DAF expression.
To test this hypothesis, we screened the DAF gene sequences relevant to the classical complement pathway and found an
association between myasthenics with EOM paresis and the DAF regulatory region c.-198C4G SNP (odds ratio¼8.6;
P¼0.0003). This single nucleotide polymorphism (SNP) results in a twofold activation of a DAF 50-flanking region luciferase
reporter transfected into three different cell lines. Direct matching of the surrounding SNP sequence within the DAF regulatory
region with the known transcription factor-binding sites suggests a loss of an Sp1-binding site. This was supported by the
observation that the c.-198C4G SNP did not show the normal lipopolysaccharide-induced DAF transcriptional upregulation in
lymphoblasts from four patients. Our findings suggest that at critical periods during autoimmune MG, this SNP may result in
inadequate DAF upregulation with consequent complement-mediated EOM damage. Susceptible individuals may benefit from
anti-complement therapy in addition to immunosuppression.
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Introduction
Antibody-mediated damage at the neuromuscular junction
in myasthenia gravis (MG) is largely because of concomi-
tant activation of the classical complement pathway.
1,2
Although IgG1–acetylcholine receptor (AChR) complexes
can modulate AChRs by cross-linking and accelerating
degradation as well as functionally blocking AChRs, it is
the activation of complement through successive stimula-
tion of C3 and C5 convertase that ultimately results in a
membrane attack complex with lysis of the post-synaptic
muscle endplate.
3,4 There is a body of data implicating
complement in the pathophysiology of MG; complement
deposition has been observed at the muscle endplate of
human subjects with MG and in experimental allergic MG
(EAMG).
1,3,5 Animal models became resistant to the
induction of EAMG when circulating complement was
either depleted by cobra venom toxin or functionally
inhibited by the administration of a monoclonal C5
antibody or soluble C1 receptor.
6–8 Rodent models either
deficient in C4, critical for the generation of C3 convertase,
or C6, an important constituent of the membrane attack
complex, were more resistant to EAMG induction
9,10 and
showed less endplate damage than control animals.
9
Complement-mediated damage at the muscle endplate
has been shown to result in the loss of AChRs, alter the
architecture of endplate folds and likely reduce Na
þ
channel density in these folds, all of which affects
neuromuscular transmission.
11
Innate complement control mechanisms include comple-
ment regulatory proteins expressed on all serum-exposed
cells, each of which intervenes at key points in the cascade,
thereby protecting cell membranes against autologous
complement damage. One of these is decay-accelerating
factor (DAF) or CD55, and its main function is to bind and
inactivate pre-formed C3/C5 convertase complexes.
12,13
Both DAF and, another complement regulator, CD59,
appear to be concentrated at neuromuscular junctions
a n db o t hc a nb eu p r e g u l a t e db ym u s c l ec e l l s .
14 Of the two,
DAF appears to be more crucial in the protection of muscle
against EAMG-associated complement injury,
15 although
this finding may be mouse strain-specific.
16 Daf1-deficient
animals compared with wild-type (WT) littermates were
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severe complement-mediated muscle damage.
2,15
From clinical observations, a larger proportion of
South African (SA) subjects with African genetic ancestry
(either indigenous Black African (Black) or mixed
ancestry (M/A)) were noted to develop severe myasthe-
nic extraocular muscle (EOM) dysfunction (including
levator palpebrae muscles); almost half of these patients
only developed this ocular phenotype while receiving
standard immunosuppressive therapy, with the remain-
ing MG signs responding appropriately to therapy.
17
DAF provides substantial complement protection for eye
tissues,
18 and as the expression of DAF in the EOMs of
mice is substantially lower than other skeletal muscle
allotypes,
14,19 we reasoned that MG patients developing
severe EOM damage may have lower background or
inducible DAF expression.
The DAF gene maps to chromosome 1q32 and consists
of 14 exons that encode a 70-kDa protein.
20,21 The
functional sites are organized into four N-terminal
complement control protein (CCP) domains separated
from a C-terminal glycophosphatidylinositol (GPI) mem-
brane anchor by the serine, threonine and proline stalk.
22
Site-directed mutagenesis determined that the CCP 2 and
3 regions are critical for the classical pathway C3
convertase regulatory activity,
23 and are encoded by
exons 3, 4 and 5.
20 A number of DAF isoforms have been
characterized. The two major splice variants are mem-
brane-bound DAF (gDAF) and soluble DAF (sDAF)
found in plasma and body fluids.
21,24 Isoform switching
from sDAF to gDAF occurs when exon 10 is spliced
out.
21 The last exon encodes the GPI anchor, which is
attached and guided by a critical signal, the
C-terminal serine 319, to the cell membrane for insertion.
25
The ‘minimal DAF promoter’ or the 50-flanking region
has several regulatory regions that show functional
variation in different cell lines, suggesting tissue speci-
ficity in transcriptional regulation.
26–28 Furthermore,
there is increasing evidence of single nucleotide poly-
morphisms (SNPs) in regulatory elements influencing
variation in gene expression and susceptibility to
complex diseases.
29 On the basis of these observations,
we hypothesize that DAF expression may be lower than
normal or not properly upregulated during ‘inflamma-
tory stress,’ resulting in inadequate complement protec-
tion in the EOMs of a subgroup of individuals with MG.
We screened the DAF gene sequence of subjects with the
severe EOM phenotype focusing initially on exons
encoding the regions important in the regulation of the
classical complement pathway, and second on the DAF
gene regulatory sequence, which would influence gene
expression. We found evidence that an alteration of the
DAF regulatory sequence, the c.-198C4G SNP, associates
with a severe EOM outcome in MG and suggest (a) the
loss of a Sp1-binding site and (b) that altered upregula-
tion of DAF expression to a lipopolysaccharide (LPS)-like
stimulus during the MG disease course may influence
MG morbidity.
Results
Clinical data
The EOM outcome to standard MG therapy was based
on data from symptom onset to analysis over a median
period of 6 years (interquartile range (IQR): 3, 13.5); the
observational period for Black (median: 7.0 years; IQR:
2.5, 11.75) and White patients (median: 5.0 years; IQR:
2.5, 7.0) (P¼0.104) was similar, although M/A patients
had been followed for longer period (median: 8.5 years;
IQR: 3.55, 17.75). Genotyping was carried out in 139 MG
patients and 167 controls (Table 1). See additional
material (Supplementary Table S1) for the distribution
of MG subtypes studied. At diagnosis, most MG patients
had paresis of at least one EOM that, in the majority,
subsequently resolved on immunosuppressive therapy.
17
However, during the MG disease course and on
immunotherapy, patients of African ancestry were more
likely to develop dysfunction of at least one EOM (26.5%;
95% CI: 18.6, 35.7) compared with Whites (15.2%; 95% CI:
5.8, 30.4), with an even greater racial disproportion when
those with pareses of five or more EOMs are categorized
(20.6 vs 9.1%, respectively) (Table 1). Of the 30 subjects
with more than one EOM paresis, only 1 had ocular MG
(complete ophthalmoplegia previously described
17), 3
were seronegative (and MuSK negative) and 1 had
concomitant thyroid disease (excluded from analysis).
Those with complete ophthalmoplegia also had bilateral
ptosis at rest.
17 Supplementary Figure 1 shows the
distribution of EOM dysfunction in those with African
ancestry compared with those without; all the subjects
with pareses of X5 EOMs had at least unilateral ptosis at
rest and those with pareses of X9 EOMs also had
bilateral ptosis.
DAF sequencing
Exons 3, 4 and 5 were sequenced in 49, 56 and 44
individuals with MG, respectively, and the results
showed no differences to the published sequences
(http://www.ncbi.nlm.nih.gov/entrez). Sequencing of
the DAF upstream regulatory region
26 detected two
variants (rs28371585 and rs28371586) with the SA sub-
population control frequencies similar to those of
previously genotyped racially matched controls; SA
White controls were similar to European controls, and
SA Black and M/A controls were similar to African-
American controls (Table 1 and Supplementary Table S2;
http://www.ncbi.nlm.nih.gov/SNP). SNP rs28371585
(c.-244_–243insA) was found to be prevalent among
controls with African genetic ancestry (37%) and showed
a trend toward reduced prevalence among MG subjects
(26%; odds ratio¼0.61; P¼0.085) (Supplementary Table S2).
The sequence of the cDNA spanning exons 7–9/14
gDAF was normal in 10 MG subjects, including
individuals with severe MG-associated ophthalmoplegia
and refractory MG.
DAF regulatory region SNP as susceptibility allele for the
development of EOM paresis in MG
The allelic frequencies and genotypes of the DAF
c.-198C4G SNP (rs28371586) in three sub-populations
of myasthenic subjects are shown in Table 1. This SNP in
the upstream regulatory region of DAF showed no
significant association with MG subjects overall, but
was significantly more frequent among those developing
EOM paresis associated with MG. Of the 11 patients
presenting with complete ophthalmoplegia at the time of
MG diagnosis, 4 responded partially to immunotherapy
or not at all, and 2 of these had the c.-198C4G SNP. Five
patients developed complete ophthalmoplegia only after
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three had the c.-198C4G SNP. Of all the MG subjects
followed up, nine had at least one G allele, of whom only
one had full EOM movement. The highest likelihood of
developing severe ophthalmoplegia associated with MG
appears to be in a Black individual with either the G/C
or GG genotype.
The DAF c.-198C4G SNP is regulatory
The c.-198C4G SNP created through site-directed
mutagenesis in a human DAF 50-regulatory region, and
hereafter referred to as the ‘Mut DAF promoter,’
influenced basal activity of the DAF regulatory region.
In COS-7, HT1080 and C2C12 muscle cells, we showed a
2- to 2.5-fold increase in luciferase activity driven by the
Mut DAF promoter compared with the WT 50-regulatory
sequence (Figures 1a and b). Although the C2C12 muscle
cells showed evidence of myoblast differentiation after 2
(fusiform elongation and 85% confluence) to 4 days
(multinucleation) in differentiation medium, allowing
the cells to differentiate for 10 days showed no difference
in relative luciferase activity between WT and Mut DAF
vectors (Figure 1b). Figure 1c shows the absolute
quantified mRNA expression of gDAF from three
lymphoblastoid cell lines from patients with the
c.-198C4G SNP in the DAF 50-regulatory region.
Furthermore, basal DAF expression was higher in two
cell lines with the Mut DAF promoter compared with the
WT, mimicking the results of the in-vitro transfection
experiments.
Loss of a transcription factor-binding site
The transcription factor-binding site (TFBS) analysis
showed that the WT DAF 50-flanking sequence contains
an Sp1-binding site that is lost in the Mut DAF
50-flanking sequence, whereas the Mut sequence showed
gain of a nuclear factor-kB (NF-kB) TFBS. To investigate
the functional importance of the loss of an Sp1 TFBS at
c.-198C4G of the DAF regulatory region, co-transfection
experiments were carried out in HT1080 cells with an
Sp1 expression vector (pCMV-Sp1) or an empty vector
(pCMV) in addition to the Mut or WT DAF promoter
luciferase vector. Sp1 had a similar effect on both the WT
and the Mut DAF promoters (Figure 2).
The DAF 50-flanking region c.-198C4G SNP influences
LPS-induced DAF upregulation
The transcription factor Sp1 induces DAF expression in
response to LPS treatment. The expected inducible
response of the WT DAF regulatory region with an
increase in gDAF mRNA and protein expression in
response to LPS treatment compared with cells treated
with vehicle alone is shown in Figures 3a–c. However,
lymphoblasts from four MG patients with the
c.-198C4G SNP showed a reduction in gDAF mRNA
and protein expression upon LPS stimulation, presum-
ably because of the loss of the Sp1 TFBS at c.198 of the
DAF regulatory region.
Quantification of gDAF protein expression by western
blotting (Figures 3b and c) shows the WT gDAF
expression to be approximately 2.4-fold upregulated to
Table 1 Association of rs28371586 (c.-198C4G) with treatment-resistant EOM involvement in South African MG sub-populations
Subjects G allele Genotype CG+GG/CC
Phenotype N (%) Frequency OR (95% CI) P-value CC CG/GG OR (95% CI) P-value
Black EOM-N 21 (70) 0 1.0 0
EOM X1 9 (30) 0.222 12.9 (2.1–108.7) 0.006 0.555 0.444 18.4 (2.7–127.0) 0.004
EOM X5 6 (20) 0.250 14.6 (2.0–138.6) 0.009 0.500 0.500 23.0 (2.7–194.8) 0.008
C 48 0.021 0.958 0.042
M/A EOM-N 53 (74) 0.009 0.981 0.019
EOM X1 18 (25) 0.111 6.2 (1.3–29.1) 0.022 0.833 0.167 4.0 (0.8–19.7) 0.12
EOM X5 15 (21) 0.067 2.9 (0.4–17.2) 0.27 0.867 0.133 3.1 (0.5–18.5) 0.28
C 84 0.024 0.952 0.048
Afr-ancest EOM-N 75 (74) 0.006 0.987 0.013
EOM X1 27 (26) 0.148 8.6 (2.8–26.1) 0.0003 0.740 0.259 7.4 (2.2–24.1) 0.002
EOM X5 21 (21) 0.119 5.8 (1.5–20.7) 0.011 0.762 0.238 6.6 (1.8–24.0) 0.009
C 132 0.023 0.045
White
a EOM-N 28 (85) 0 1 0
EOM X1 5 (15) 0 1 0
EOM X5 3 (9) 0 1 0
C3 5 0 1 0
SNP-NCBI
(ss32475790)
Af-Amer 23 0.022 0.978 0.043
European 23 0 1 0
Abbreviations: Af-Amer, African American; Afr-ancest, African ancestry, i.e., indigenous Black Africans and those with African admixture
(M/A); C, racially matched controls; CI, 95% confidence interval; EOM, extraocular muscles; EOM-N, normal eye movements; M/A, mixed
ancestry; MG, myasthenia gravis; OR, odds ratio.
Bold values indicate the significant ORs.
aOne subject with thyroid eye disease was excluded from the analysis.
EOM X1 refers to at least 1 EOM paresed and unresponsive to therapy for several months; EOM X5 refers to paresis of at least 5 of 12 EOMs.
Odds ratio were determined relative to the normal controls and the exact P-values are two-tailed.
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mately 2.4-fold downregulated in response to LPS
treatment.
Discussion
Much data exist implicating complement as a major
effector in neuromuscular junction damage in MG.
1–12,14–16
Knockout experiments have shown that complement
regulators such as DAF, at least in the EAMG model,
influences the severity of damage by complement-fixing
a n t i b o d i e sa tt h em u s c l ee n d p l a t e .
2,15,16 Although basal
complement regulatory protein (CRP) mRNA transcripts
were lower in mouse EOMs compared with their
diaphragm muscles, the induction of EAMG resulted in
a further reduction of EOM CRP expression and particu-
larly of DAF.
14 These and other observations led to the
‘complement hypothesis,’ suggesting that a relative
deficiency of complement regulation in extraocular mus-
cles may increase their susceptibility to myasthenic
induction.
14,30 This study represents the first supportive
evidence in humans; our data show that DAF is linked to
the development of a treatment-resistant EOM phenotype
that develops in a subgroup of MG patients; myasthenic
subjects with the c.-198C4G SNP in the regulatory region
of the DAF gene have a significantly higher risk of
developing EOM pareses. The c.-198C4G SNP influences
DAF regulation and specifically the ability to upregulate
DAF expression in response to bacterial products such as
LPS, which we propose, may influence the degree of
complement-mediated endplate damage at critical periods
during the patient’s myasthenic disease course.
Transfection of the Mut DAF 50-flanking region
(containing a mutation mimicking the SNP) cloned into
a luciferase reporter vector shows the SNP to be
functional and capable of driving luciferase expression
in three different cell lines under basal conditions.
Similarly, absolute DAF mRNA expression in EBV-
transformed lymphoblasts from two individuals with
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Figure 2 Co-transfection of the DAF promoter construct and the
Sp1 vector in HT1080 cells does not alter basal activity. The average
fold change of luciferase activity from cells co-transfected with
empty vector (pCMV) as control relative to those transfected with
Sp1 transcription factor (pCMV-Sp1), in addition to either WT or
mut DAF promoter, is similar. Mean data (±s.d.) of duplicate
experiments.
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Figure 1 The c.-198C4G (mutant) DAF SNP is regulatory.
(a) Transfection of the mutant DAF regulatory construct activates
DAF promoter activity (as measured by luciferase assay) compared
with transfection with WT promoter construct in COS-7 and
HT1080 cells (normalized to 1); the plasmid pRL-TK (50ng)
containing the thymidine kinase promoter driving the expression
of a Renilla reporter was used as an internal control for transfection
efficiency and firefly luciferase activity was normalized to Renilla
luciferase activity. Results representative of two independent
experiments carried out in duplicate. (b) Luciferase assay in
C2C12 muscle cells transfected with the mutant DAF promoter
compared with WT controls (normalized to 1) shows activation at
0–2 days of differentiation. Mean data (±s.d.) of duplicate
experiments. Undiff, undifferentiated; 2dd, 2 days in differentiation;
and 10dd, 10 days in differentiation medium. (c) Quantitative RT-
PCR of gDAF mRNA extracted from lymphoblastoid cell lines from
three patients with the c.-198C4G (MG1 to MG3), one MG patient
without the SNP (WT-MG) and two controls (WT1 and WT2).
Absolute mRNA expression levels (normalized to GUS1B) are
extrapolated from a standard curve. Data (mean±s.d.) from two
independent experiments carried out in duplicate and expressed as
fold change over non-LPS controls.
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compared with that in controls. Direct matching of
known binding sites to the surrounding of the SNP
shows the Mut SNP sequence to result in a potential gain
of an NF-kB-binding site and a loss of an Sp1-binding
site present in the WT sequence. In mouse studies, the
regulatory region of Daf1 was shown to have several Sp1
transcription binding sites that are critical in the
constitutive and LPS-inducible expression of Daf in
several tissues.
28 Two of three Sp1 sites in the Daf1
promoter (þ1t o 619) were critical for the basal Daf1
promoter activity in several cell lines, whereas the
remaining non-critical Sp1 site that equates with the
Sp1 site lost in the human c.-198C4G SNP did not
influence basal transcription.
28 Interestingly, deletion of
the latter Sp1 site in mice also resulted in the activation
of Daf1-driven luciferase activity in mouse B cells.
28
Several studies have shown that bacterial LPS, a major
component of Gram-negative bacterial cell walls, upre-
gulates DAF expression (Cauvi et al.
28). LPS-induced
upregulation of the regulatory activity and the expres-
sion of Daf1 were shown in both murine lymphocyte and
macrophage cell lines but not in fibroblasts, suggesting
tissue specificity of LPS-induced DAF upregulation.
28
The LPS-induced DAF upregulation in these mouse cells
were predominantly dependent on the two Sp1 sites
most proximal to the transcription start site,
28 excluding
the herein described putative Sp1 site lost with the SNP.
Although our studies in human control lymphoblasts
showed the expected LPS treatment-induced DAF
expression, the lymphoblast containing the c.-198C4G
SNP showed a reduction in gDAF mRNA and protein
levels after LPS stimulation. Thus, the loss of the Sp1 site
at c.-198C4G in the DAF 50-flanking region results in a
downregulatory response to LPS stimulation in human
lymphoblasts. Although we cannot be certain of the
effect that the c.-198C4G SNP may have in human
extraocular muscles, we do know that the SNP showed
similar responses in transfection experiments in mouse
muscle cell lines to that observed in human lymphoblasts
under basal conditions.
Constitutive DAF expression is modulated by several
cytokines (interleukin (IL)-1, IL-6, tumor necrosis factor-a
(TNF-a), transforming growth factor (TGF)-b1 and
interferon (IFN)-g), prostaglandins and other tissue-
specific factors, although primary regulation is believed
to be at transcriptional level.
27,28 The transcription factor
Sp1 is present in the nuclei of all cells with the potential
of transcriptional activation upon binding to the DNA
Sp1-binding sites.
31 Studies have shown that cooperative
complex formation between several closely positioned
Sp1 sites are required for full gene expression.
32,33
Although proximal (to the transcription start site) Sp1-
binding sites are critical for basal transcription, such as
was seen in the Daf1 promoter,
28 the additional coopera-
tion of more distal Sp1 sites (such as that lost in our Mut
DAF with the SNP) may be necessary for an enhanced or
higher level of expression.
33,34 This does not explain why
the Mut DAF showed higher basal expression compared
with WT DAF, but it does offer an explanation for the
inability of the Mut DAF to upregulate transcription in
response to a known induction signal such as LPS.
There is increasing evidence of SNPs in the proximal
region upstream of transcription start sites to act as
specific functional cis-regulatory variants.
29,34,35 The hu-
man DAF 50-flanking sequence has been shown to harbor
several regulatory regions including an enhancer region
that is highly conserved and that encompasses the Mut
DAF SNP site ( 206/ 77 and  206/ 34).
26–28 It is
possible that the regulatory SNP at c.-198C4Gi n
humans results in increased DAF basal promoter activity
either due to functional loss of an inhibitory element or
Figure 3 Effect of LPS treatment on gDAF RNA and protein expression in lymphoblasts. (a) Total RNAwas extracted from lymphoblast cell
lines from three controls (WT1 and WT2 and one MG patient without the SNP, WT-MG) and four MG patients with the c.-198C4G SNP (MG1
to MG4), with and without LPS stimulation (10mg/ml) for 6h. Relative expression (normalized to GUS1B) by qRT-PCR is shown expressed as
fold change over non-LPS control for each cell line (normalized to 1). Data (mean±s.d.) from triplicate experiments. (b) Western blot analysis
of DAF protein levels in control (WT1) and MG patient (MG1) derived cell lines. The cells were treated with 10mgml
 1 of LPS for 6h. Protein
was extracted under non-reducing conditions and quantified using BCA standard curve method (Materials and methods). For each sample,
30mg of protein was loaded on an SDS-PAGE gel and p38 was used as a loading control to ensure equal loading of protein. DAF protein levels
increased in control cell line but decreased in the MG patient cell line on treatment with LPS. (c) The bar graph represents quantitative DAF
protein results by showing densitometry readings from the autoradiograph of DAF protein levels normalized to p38 protein levels. For the
control cell line, DAF protein levels showed an increase of approximately two-folds as a result of LPS treatment. On the contrary, the MG SNP
cell line showed a decrease of approximately two-fold when treated with LPS.
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of the Mut 50-flanking region suggested the gain of a
NF-kB-binding site. The NF-kB/Rel family of transcrip-
tion factors is involved in a wide range of inflammatory
signaling accomplished either by functional interaction
with other transcription factors or by variation in the
composition of the NF-kB dimers that translocate to the
nucleus and bind DNA.
36 Subtle differences in NF-kB-
binding sites may favor certain dimer combinations with
varied functional transcriptional consequences.
36 We
plan to study the effects of the putative gain of a
NF-kB TFBS in the future.
DAF has other functions apart from complement
regulation; antigen-primed T cells deficient of the Daf1
gene showed enhanced responsiveness and greater pro-
inflammatory cytokine production influencing inflam-
matory-associated injury in a tissue microenviron-
ment.
37,38 Furthermore, the augmented T-cell
responsiveness to activation stimuli in Daf1 knockout
mice studies persisted for weeks.
38 A recent study in
EAMG suggests that inhibiting complement at the C5
activation step, a DAF target, may also influence the
humoral response with altered antibody profiles.
39 Thus,
the effect of the c.-198C4G SNP on DAF regulation
during the autoimmune response in a compartment such
as the EOM may occur at both complement and T-cell
modulation levels. Reviewing the clinical data on our
cases developing the severe ocular phenotype,
17 it was
evident that persistent non-fatigable EOM pareses often
only developed months into the MG disease process,
suggesting that it was dependent on a critical factor(s)
additional to the autoantibody-mediated immune
response.
In humans, dysfunctional DAF is implicated in the
acquired condition of paroxysmal nocturnal hemoglobi-
nuria, in which erythrocytes develop an increased
sensitivity to complement lysis.
40,41 Moreover, a few rare
individuals have been identified as having the Cromer
phenotype of blood group antigens (INAB), in whom
polymorphisms within the DAF gene result in low or no
DAF expression.
42 These individuals are otherwise well,
although some have developed inflammatory bowel
disease.
43 Although Daf deficiency in knockout mouse
models resulted in more severe generalized MG, we have
not been able to find any other abnormalities in the DAF
gene to explain the pathogenesis in all the patients in our
cohort developing severe ophthalmoplegia; the coding
regions for CCP 2 and 3 were screened for polymorph-
isms in a range of myasthenic individuals, and the cDNA
region encoding the stalk and GPI-attachment region for
gDAF was screened in a few highly selected refractory
MG subjects, suggesting an intact signal for membrane
targeting of gDAF. Another issue that we have been
unable to address is the tissue specificity of DAF
regulation or the possible context specificity of the
regulatory SNP in EOM tissue. Peripheral B lymphocytes
is not ideal for studying LPS-induced DAF expression,
44
and our hypothesis is based on DAF expression in
human EOMs that are unobtainable, specifically when
the tissue destructive phase is active. Interestingly, in a
systemic autoimmune disease mouse model, the protec-
tive effect of Daf1 on an autoimmune genetic background
influenced tissue-specific skin inflammation.
45 We
suggest a similar tissue-specific effect of DAF, which in
certain conditions such as that mimicked by LPS
influences the EOM outcome in a subgroup of patients
with active MG.
In conclusion, we present evidence for the first time
that the complement-regulating protein DAF may be
critical for protecting the integrity of EOMs under certain
inflammatory conditions mimicked by bacterial LPS in
the setting of MG. MG subjects with the c.-198C4G SNP
in the DAF regulatory region have an added risk of
developing ophthalmoparesis, probably because of in-
sufficient upregulation of DAF expression at critical
periods of the autoimmune process rendering their
EOMs vulnerable to complement-mediated damage.
Complement inhibition therapy with a blocking anti-C5
antibody has shown promise in a rodent model of
EAMG.
46 A candidate therapy in our patients would be
eculizumab, a monoclonal antibody to C5 that has shown
efficacy in paroxysmal nocturnal hemoglobinuria.
47
Potentially, susceptible MG patients would be screened
for the polymorphism and as soon as treatment-resistant
ophthalmoparesis ensues, appropriate additional anti-
complement therapy may be initiated. Intravenous
immunoglobulin also reduces complement factors
C3a and C5a,
48 and, although expensive, would be a
reasonable intervention to attempt early on in susceptible
individuals in an effort to reduce the significant
morbidity associated with ophthalmoplegic complications.
Materials and methods
Patients
Peripheral blood was collected from 139 unrelated MG
patients, diagnosed as previously described.
17 Observa-
tional data were collected at each clinic visit. Owing to a
high proportion of EOM dysfunction noted in our
patients, a grading system for scoring limitation of
EOMs was introduced to quantify the number of EOMs
showing limitation of movement;
17 Supplementary
Figure S1 denotes the number of individuals with EOM
paresis at rest (excluding those whose EOM show
fatigability). EOM paresis scoring was carried out before
and independent of genotyping.
In addition, 167 healthy controls (hospital or university
employees) were recruited for the study and informed
written consent was obtained from patients and controls
for blood sampling and DNA analysis. The subjects
categorized themselves according to SA census racial
categories as White (European ancestry), M/A or Black
(indigenous African). The M/A sub-population is com-
posed of an admixture of Khoi San, Indian, Indonesian,
Black African and European ancestors. Permission for
the study was granted by the UCT Research Ethics
committee.
DNA was extracted using the Genomic DNA purifica-
tion Kit (PUREGENE DNA Purification System, Gentra
Systems, Minneapolis, MN, USA). cDNA was prepared
from the total mRNA of selected patients and controls
using the PAXgene tubes and Blood RNA extraction Kit
(PreAnalytiX, Qiagen, Darmstadt, Germany).
PCR
Exons 3, 4 and 5 were amplified from genomic DNA
using intronic primers spanning those exons. The gDAF
isoform was amplified from cDNA templates using a
sense primer upstream of the serine 319 site and an
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thereby excluding exons 10–13 in the PCR product. All
oligonucleotides were designed from sequences listed in
the human genome database (http://www.ncbi.nlm.
nih.gov/entrez) (Table 2). Generally, PCR of exons 3, 4
and 5 was carried out in a volume of 25ml using 100ng of
genomic DNA and a final concentration of 10pmol of
each primer, 200mM dNTPs, 1  BioTaq reaction buffer,
1.5mM MgCl2 and 1U BioTaq DNA polymerase (Bioline
Ltd, London, UK). The amplification conditions for
exons 4 and 5 were as follows: 941C (5min) followed
by 25 cycles at 941C (30s), 631C (30s), 721C (30s) and a
final extension at 721C (7min) in a GeneAmp PCR
System 2700 (Applied Biosystems, Foster City, CA, USA).
Touchdown PCR was used for exon 3 (60–561C) and
exons 7–9/14 (gDAF) (53–501C). The high GC content of
the DAF regulatory region was optimally amplified
using 1  FailSafe buffer (Epicentre Biotechnologies,
Madison, WI, USA) at 601C annealing temperature.
Sequencing
Cycle sequencing reactions were carried out using the
BigDye Terminator Cycle Version 3.1 Sequencing Kit
according to the manufacturer’s instructions (Applied
Biosystems) and analyzed on an ABI Prism 3100
automated sequencer (Applied Biosystems) using the
ABI DNA Sequencing Analysis Software version 3.7. The
sequences were analyzed for any changes from the
known sequence by using the Clustal Alignment tool in
BioEdit version 7.0. (Ibis Biosciences, Carlsbad, CA,
USA).
Quantitative real-time PCR
RNA was extracted from EBV-transformed B-cell lines
using the RNeasy Plus Mini kit (Qiagen). Reverse
transcription of RNA (1mg) was carried out using the
ImProm-II kit from Promega (Madison, WI, USA) as
recommended by the manufacturer. Using 1ml of cDNA,
PCR was conducted using SensiMix Lite Kit (Quantace,
London, UK) with minor modification to the manufac-
turer’s protocol. Real-time PCR was carried out on a
LightCycler 2 (Roche, Mannheim, Germany) and ana-
lyzed using the LightCycler software version 3.5. The
cycling conditions were as follows: 15min at 951C for the
initial activation of the enzyme, followed by 35 cycles of
denaturation (5s at 951C), annealing (3s at 571C) and
extension (5s at 721C). Melting curve analysis was
carried out to ensure product specificity by subjecting the
samples to 951C, followed by cooling to 651C with a
ramp rate of 0.11C/s. Each DNA sample was quantified
in duplicate and a negative control was run with every
assay to assess overall specificity. Data was analyzed
using the 2 DDCT method.
49
Relative gDAF mRNA expression levels were normal-
ized to the housekeeping gene, Glucuronidase B
(GUS1B), for each reaction. GUS1B was amplified
separately in 10ml reaction volumes, as described for
DAF, using the appropriate primer set and at annealing
temperature of 551C. The melting curve analysis was the
same as for DAF.
Relative and absolute quantification methods were
used to analyze the basal DAF mRNA expression levels.
For LPS-induced expression, triplicate experiments were
carried out for each cell line and expressed as fold
change over non-LPS-treated controls. The relative
quantification method was used to evaluate the quanti-
tative real-time PCR data.
50,51 Briefly, this was accom-
plished by comparing the threshold cycle (Ct) values of
gDAF with that of the housekeeping gene to account for
differences in quality and quantity between individual
samples. Standard curves were generated using serial
dilutions from 10
3 to 10
7 concentrations of the external
reference sample and were used for amplification
efficiency correction. The dilutions were run in tripli-
cates. An external reference cDNA sample chosen from
the healthy controls was always included in each run to
account for variations between runs.
The external standard reference sample enabled us to
compare different PCR runs and for efficiency correction.
Crossing point cycle numbers were plotted against the
logarithm of the concentration of each sample to generate
the standard curve. The slopes (S) were then obtained
and the amplification efficiencies (E) were calculated
using the formula E¼10
( 1/S) 1. Calculated efficiency
was 88.4% for gDAF and 86.9% for GUS1B.
Cell culture
COS-7 monkey kidney epithelial, HT1080 human fibro-
sarcoma (ATCC CCL-120) and the C2C12 mouse myo-
blast cell line were maintained in DMEM (Dulbecco’s
modified Eagle’s medium), supplemented with 10% of
fetal calf serum (Gibco, St Louis, MO, USA) and 1%
penicillin–streptomycin (P/S) at 371C (95% air, 5% CO2,
65% humidity). C2C12 cells were allowed to differentiate
by switching growth medium to differentiating medium
(DMEM supplemented with 2% horse serum (HS) and
Table 2 Regions amplified in the DAF gene
Oligonucleotides Sequence Annealing temperature (1C) Number of bases
Promoter sense 50-ACACCCCGTTTGTTTTACG-30 60 20
Promoter antisense 50-GCACAACAGCACCAGCAG-30 60 18
Exon 3 sense 50-TTGCTGCTTTTGTTAATACTTTTAGG-30 60–56 26
Exon 3 antisense 50-TATTTCCCCCAAACACCAGA-30 60–56 20
Exon 4 sense 50-CATAGTTACCTTCTTTGTGTGTATGC-30 63 26
Exon 4 antisense 50-GTCCTAATTTGTTTTCTCATTTCC-30 63 24
Exon 5 sense 50-CCTGGAGAATTTGAGGAAAGT-30 63 21
Exon 5 antisense 50-GCCTCACAATCTGAGTGCTT-30 63 20
cDNA exon 7–9/14 sense 50-GGATTCACCATGATTGGAGAGC-30 53–50 22
cDNA exon 7–9/14 antisense 50-TGTGCCCAGATAGAAGAC-30 53–50 19
Abbreviation: DAF, decay-accelerating factor.
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differentiating time points.
To establish the human lymphoblastoid cell lines by
EBV transformation, 10ml heparinized blood was
obtained from four MG patients with c.-198C4G SNP
and three control individuals. The DAF 50-regulatory
sequence was verified in all individuals using cycle
sequencing as described above. The EBV-transformed
lymphoblasts were maintained in DMEM supplemented
with 10% FBS and 1% P/S and checked for mycoplasma
infection by Hoechst staining. For LPS (Sigma-Aldrich,
Saint Louis, MO, USA) stimulation, cells were treated, as
previously described, with 10mgml
 1 LPS for 6h
52 before
harvesting for mRNA.
Plasmid constructs
The WT DAF promoter construct cloned into a pGL3-
basic firefly luciferase reporter vector was gifted by Dr
DuBois.
53 The Mut construct was generated by site-
directed mutagenesis using the QuickChange kit (Stra-
tagene, La Jolla, CA, USA) to mutate the C at c.-198 to
G using the WT DAF promoter construct as a template.
The mutant sequence was verified using an ABI Prism
3100 automated sequencer before further evaluation. The
pRL-TK vector (Promega, Madison, WI, USA) was used
as an internal control reporter to test for transfection
efficiency. The pCMV-Sp1 expression vector was ob-
tained from Dr Tijan (Department of Molecular and Cell
Biology, University of California, Berkeley, CA, USA)
through Addgene.
Transfections and reporter assays
Cells were plated at 1.5 10
5 cells per ml in six-well
plates 1 day before transfection. Non-liposomal gene
transfer was carried out using FuGENE 6 (Roche, Basel,
Switzerland) according to the manufacturer’s instruc-
tions with 1mg of DNA consisting of the WT or the Mut
DAF reporter construct, and/or Sp1 expression vector
and the internal control vector. At 48h after transfection,
cells were analyzed for luciferase activity using the Dual-
Luciferase Reporter Assay (Promega) following the
manufacturer’s instructions and quantified using a
Luminoskan Ascent luminometer (Thermo LabSystems,
Franklin, MA, USA). All transfections were carried out in
duplicate.
TFBS analysis
We performed a direct matching of the known TFBSs
contained in the TRANSFAC Professional database
(v.11.2).
54 This was carried out using the Patch program
of the TRANSFAC Suite.
54 We matched the motifs with a
length of 7bp, with no mismatch between the template
motif and the matched sequence. We considered that the
motif is affected by the SNP if it includes the SNP
nucleotide. Our results indicate that an Sp1-binding site
in genomic sequence (C nucleotide version) is lost when
G nucleotide replaced C nucleotide. The new putative
TFBS obtained was that of a NF-kB-binding site.
Western blot
Whole-cell extracts were prepared from cells using a
lysis buffer containing: 150mM NaCl, 1% Triton X-100,
50mM Tris-HCl (pH 8.0), supplemented with 1mgml
 1
of aprotinin, 1mgml
 1 of Pepstatin A and 2mM of
phenylmethanesulfonyl fluoride protease inhibitors
(Sigma-Aldrich). Proteins were resolved on 8% SDS–
polyacrylamide gels under non-reducing conditions and
transferred to Hybond ECL (Amersham Biosciences,
Piscataway, NJ, USA). The membranes were probed with
appropriate primary antibodies and detected using
peroxidase-conjugated anti-mouse or anti-rabbit antibo-
dies (1:5000) and visualized by enhanced chemilumines-
cence (Pierce, Rockford, IL, USA). The primary
antibodies used were mouse monoclonal anti-DAF
(1:100; BRIC 216, IBGRL, London, UK) and anti-p38
(1:5000; Cell Signaling Technology Inc., Beverly, MA,
USA).
Statistical analysis
Allele and genotype frequencies were compared between
groups using 2 2 tables to obtain a Yates corrected w
2;
if a cell value was o5 the Fisher exact test was used
(http://www.openepi.com). Odds ratios and their 95%
confidence intervals (CIs) were determined relative to
control populations. The remaining calculations were
carried out with Statistica 8.0 software (StatSoft Inc,
Tulsa, OK, USA). Skewed data are represented by
median and IQR. The differences in the time of
evaluation between the racial groups were assessed
using the Kruskal–Wallis test. Po0.05 (two-tailed) was
considered statistically significant.
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